New research reveals that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional diet and exercise plans.
Research printed in a prominent medical journal demonstrates that while obese individuals often shed substantial amounts of their total mass while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Users buying such treatments need to be informed of the risk of quick weight regain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to starting weight within about 18 months.
Analyzing Approaches
The research, which reviewed 37 of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with older methods.
Researchers emphasize that individuals who lose weight through lifestyle changes alone typically see a more gradual creep back—around 100 grams monthly—after stopping.
Understanding the Fast Regain
Experts propose the mechanism of the jabs is key to understanding the accelerated regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than the body's typical production might result in the system to produce less of its endogenous hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in hunger is uncontrolled, making excessive eating a significant risk."
A Chronic Issue?
Medical guidelines recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals argue that, due to the high risk of relapse, the therapy is often long-term.
This view is reinforced by pharmaceutical companies, who say that the results "emphasize the persistent nature of excess weight," similar to managing diseases like high blood pressure.
Patient Experiences
Individuals who have stopped the medication explain a intense return of hunger.
"It felt as if something that goes on and I was suddenly starving," recalled an individual.
The struggle is compounded if users have not adopted permanent dietary or behavioural modifications during therapy.
Significant Adoption
Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is higher among females than males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic cure and long-term success likely depends on integrated lifestyle support.
